Hudson Bay Capital Management LP Has $11.27 Million Stake in Genmab A/S (NASDAQ:GMAB)

Hudson Bay Capital Management LP raised its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 103.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 540,000 shares of the company's stock after acquiring an additional 275,000 shares during the period. Hudson Bay Capital Management LP owned approximately 0.08% of Genmab A/S worth $11,270,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC lifted its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after purchasing an additional 2,496 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GMAB has been the subject of a number of analyst reports. BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Genmab A/S has an average rating of "Moderate Buy" and a consensus price target of $39.17.

Genmab A/S Stock Down 1.2%

Shares of Genmab A/S stock traded down $0.23 during midday trading on Wednesday, hitting $19.08. The company's stock had a trading volume of 1,706,170 shares, compared to its average volume of 1,105,998. The stock has a 50-day simple moving average of $19.90 and a 200-day simple moving average of $20.82. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41. The firm has a market capitalization of $12.23 billion, a P/E ratio of 10.97, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The business had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. As a group, sell-side analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.